Digitalni repozitorij raziskovalnih organizacij Slovenije

Izpis gradiva
A+ | A- | SLO | ENG

Naslov:Treatment patterns, testing practices, and outcomes in the pre-FLAURA era for patients with EGFR mutation-positive advanced NSCLC : a retrospective chart review (REFLECT)
Avtorji:Addeo, Alfredo (Avtor)
Hochmair, Maximilian J (Avtor)
Janžič, Urška (Avtor)
Dudnik, Elizabeth (Avtor)
Charpidou, Andriani (Avtor)
Płużański, Adam (Avtor)
Ciuleanu, Tudor (Avtor)
Shterev Donev, Ivan (Avtor)
Elbaz, Judith (Avtor)
Aarøe, Jørgen (Avtor)
Ott, René (Avtor)
Peled, Nir (Avtor)
Jezik:Angleški jezik
Tipologija:1.01 - Izvirni znanstveni članek
Organizacija:Logo UKPBAG - Univerzitetna klinika za pljučne bolezni in alergijo Golnik
Povzetek:Background. Immunotherapy with immune checkpoint inhibitors (ICIs) recently became the standard treatment for patients with advanced non-small cell lung cancer (NSCLC). Here, we present the first results of a real-world observational study on the effectiveness of ICI monotherapy in patients with advanced NSCLC treated at a single academic center in a Central and Eastern European (CEE) country. Materials and methods. Overall, 66 consecutive patients with advanced NSCLC treated with ICIs in everyday clinical practice, either with first-line pembrolizumab (26 patients) or second-line atezolizumab, nivolumab, or pembrolizumab (40 patients), from August 2015 to November 2018, were included. All data were retrieved from a hospital lung cancer registry, in which the data is collected prospectively. Results. Included patients had a median age of 64 years, most were male (55%), 6% were in performance status >/=2, and 18% had controlled central nervous system metastases at baseline. In first-line, the median progression-free survival (mPFS) was 9.3 months, while the median overall survival (mOS) was not reached. The 1-year overall survival (OS) was 62%. In second-line, the mPFS and mOS were 3.5 months and 9.9 months, respectively, with a 1-year OS of 35%. In the overall population, adverse events of any grade were recorded in 79% of patients and of severe grade (3-4) in 12% of patients. Conclusion. The first real-world outcomes of NSCLC immunotherapy from a CEE country suggest comparable effectiveness to those observed in clinical trials and other real-world series, mainly coming from North America and Western European countries. Further data to inform on the real-world effectiveness of immunotherapy worldwide are needed.
Ključne besede:non-small cell lung carcinoma, immunotherapy, advanced non-small cell lung cancer, real-world data, Europe, Central Europe, Eastern Europe
Leto izida:2021
Založnik:Sage
Izvor:Velika Britanija
UDK:616-006
ISSN pri članku:1758-8359
COBISS_ID:89318403 Povezava se odpre v novem oknu
DOI:10.1177/17588359211059874 Povezava se odpre v novem oknu
Opombe:Nasl. z nasl. zaslona; Soavtorica iz Slovenije: Urška Janžič; Opis vira z dne 14. 12. 2021;
Število ogledov:209
Število prenosov:66
Datoteke:URL URL - Izvorni URL, za dostop obiščite https://journals.sagepub.com/doi/pdf/10.1177/17588359211059874
 
Nadgradivo:Ther. adv. med. oncol.
SAGE Publications
 
Metapodatki:XML RDF-CHPDL DC-XML DC-RDF
Avtorske pravice:© The Author(s), 2021
:
  
Postavite miškin kazalec na naslov za izpis povzetka. Klik na naslov izpiše podrobnosti ali sproži prenos.


Licence

Licenca:CC BY-NC 4.0, Creative Commons Priznanje avtorstva-Nekomercialno 4.0 Mednarodna
Povezava:http://creativecommons.org/licenses/by-nc/4.0/deed.sl
Opis:Licenca Creative Commons, ki prepoveduje komercialno uporabo, vendar uporabniki ne rabijo upravljati materialnih avtorskih pravic na izpeljanih delih z enako licenco.
Začetek licenciranja:27.10.2021

Nazaj